Cargando…

Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies

Antibody-dependent cellular cytotoxicity (ADCC) has been correlated with reduced risk of human immunodeficiency virus type 1 (HIV-1) infection in several preclinical vaccine trials and in the RV144 clinical trial, indicating that this is a relevant antibody function to study. Given the diversity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mielke, Dieter, Stanfield-Oakley, Sherry, Borate, Bhavesh, Fisher, Leigh H., Faircloth, Katelyn, Tuyishime, Marina, Greene, Kelli, Gao, Hongmei, Williamson, Carolyn, Morris, Lynn, Ochsenbauer, Christina, Tomaras, Georgia, Haynes, Barton F., Montefiori, David, Pollara, Justin, deCamp, Allan C., Ferrari, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791251/
https://www.ncbi.nlm.nih.gov/pubmed/34730393
http://dx.doi.org/10.1128/JVI.01643-21
_version_ 1784640165242732544
author Mielke, Dieter
Stanfield-Oakley, Sherry
Borate, Bhavesh
Fisher, Leigh H.
Faircloth, Katelyn
Tuyishime, Marina
Greene, Kelli
Gao, Hongmei
Williamson, Carolyn
Morris, Lynn
Ochsenbauer, Christina
Tomaras, Georgia
Haynes, Barton F.
Montefiori, David
Pollara, Justin
deCamp, Allan C.
Ferrari, Guido
author_facet Mielke, Dieter
Stanfield-Oakley, Sherry
Borate, Bhavesh
Fisher, Leigh H.
Faircloth, Katelyn
Tuyishime, Marina
Greene, Kelli
Gao, Hongmei
Williamson, Carolyn
Morris, Lynn
Ochsenbauer, Christina
Tomaras, Georgia
Haynes, Barton F.
Montefiori, David
Pollara, Justin
deCamp, Allan C.
Ferrari, Guido
author_sort Mielke, Dieter
collection PubMed
description Antibody-dependent cellular cytotoxicity (ADCC) has been correlated with reduced risk of human immunodeficiency virus type 1 (HIV-1) infection in several preclinical vaccine trials and in the RV144 clinical trial, indicating that this is a relevant antibody function to study. Given the diversity of HIV-1, the breadth of vaccine-induced antibody responses is a critical parameter to understand if a universal vaccine is to be realized. Moreover, the breadth of ADCC responses can be influenced by different vaccine strategies and regimens, including adjuvants. Therefore, to accurately evaluate ADCC and to compare vaccine regimens, it is important to understand the range of HIV Envelope (Env) susceptibility to these responses. These evaluations have been limited because of the complexity of the assay and the lack of a comprehensive panel of viruses for the assessment of these humoral responses. Here, we used 29 HIV-1 infectious molecular clones (IMCs) representing different Envelope subtypes and circulating recombinant forms to characterize susceptibility to ADCC from antibodies in plasma from infected individuals, including 13 viremic individuals, 10 controllers, and six with broadly neutralizing antibody responses. We found in our panel that ADCC susceptibility of the IMCs in our panel did not cluster by subtype, infectivity, level of CD4 downregulation, level of shedding, or neutralization sensitivity. Using partitioning around medoids (PAM) clustering to distinguish smaller groups of IMCs with similar ADCC susceptibility, we identified nested panels of four to eight IMCs that broadly represent the ADCC susceptibility of the entire 29-IMC panel. These panels, together with reagents developed to specifically accommodate circulating viruses at the geographical sites of vaccine trials, will provide a powerful tool to harmonize ADCC data generated across different studies and to detect common themes of ADCC responses elicited by various vaccines. IMPORTANCE Antibody-dependent cellular cytotoxicity (ADCC) responses were found to correlate with reduced risk of infection in the RV144 trial of the only human HIV-1 vaccine to show any efficacy to date. However, reagents to understand the breadth and magnitude of these responses across preclinical and clinical vaccine trials remain underdeveloped. In this study, we characterize HIV-1 infectious molecular clones encoding 29 distinct Envelope strains (Env-IMCs) to understand factors that impact virus susceptibility to ADCC and use statistical methods to identify smaller nested panels of four to eight Env-IMCs that accurately represent the full set. These reagents can be used as standardized reagents across studies to fully understand how ADCC may affect efficacy of future vaccine studies and how studies differ in the breadth of responses developed.
format Online
Article
Text
id pubmed-8791251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-87912512022-02-09 Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies Mielke, Dieter Stanfield-Oakley, Sherry Borate, Bhavesh Fisher, Leigh H. Faircloth, Katelyn Tuyishime, Marina Greene, Kelli Gao, Hongmei Williamson, Carolyn Morris, Lynn Ochsenbauer, Christina Tomaras, Georgia Haynes, Barton F. Montefiori, David Pollara, Justin deCamp, Allan C. Ferrari, Guido J Virol Vaccines and Antiviral Agents Antibody-dependent cellular cytotoxicity (ADCC) has been correlated with reduced risk of human immunodeficiency virus type 1 (HIV-1) infection in several preclinical vaccine trials and in the RV144 clinical trial, indicating that this is a relevant antibody function to study. Given the diversity of HIV-1, the breadth of vaccine-induced antibody responses is a critical parameter to understand if a universal vaccine is to be realized. Moreover, the breadth of ADCC responses can be influenced by different vaccine strategies and regimens, including adjuvants. Therefore, to accurately evaluate ADCC and to compare vaccine regimens, it is important to understand the range of HIV Envelope (Env) susceptibility to these responses. These evaluations have been limited because of the complexity of the assay and the lack of a comprehensive panel of viruses for the assessment of these humoral responses. Here, we used 29 HIV-1 infectious molecular clones (IMCs) representing different Envelope subtypes and circulating recombinant forms to characterize susceptibility to ADCC from antibodies in plasma from infected individuals, including 13 viremic individuals, 10 controllers, and six with broadly neutralizing antibody responses. We found in our panel that ADCC susceptibility of the IMCs in our panel did not cluster by subtype, infectivity, level of CD4 downregulation, level of shedding, or neutralization sensitivity. Using partitioning around medoids (PAM) clustering to distinguish smaller groups of IMCs with similar ADCC susceptibility, we identified nested panels of four to eight IMCs that broadly represent the ADCC susceptibility of the entire 29-IMC panel. These panels, together with reagents developed to specifically accommodate circulating viruses at the geographical sites of vaccine trials, will provide a powerful tool to harmonize ADCC data generated across different studies and to detect common themes of ADCC responses elicited by various vaccines. IMPORTANCE Antibody-dependent cellular cytotoxicity (ADCC) responses were found to correlate with reduced risk of infection in the RV144 trial of the only human HIV-1 vaccine to show any efficacy to date. However, reagents to understand the breadth and magnitude of these responses across preclinical and clinical vaccine trials remain underdeveloped. In this study, we characterize HIV-1 infectious molecular clones encoding 29 distinct Envelope strains (Env-IMCs) to understand factors that impact virus susceptibility to ADCC and use statistical methods to identify smaller nested panels of four to eight Env-IMCs that accurately represent the full set. These reagents can be used as standardized reagents across studies to fully understand how ADCC may affect efficacy of future vaccine studies and how studies differ in the breadth of responses developed. American Society for Microbiology 2022-01-26 /pmc/articles/PMC8791251/ /pubmed/34730393 http://dx.doi.org/10.1128/JVI.01643-21 Text en Copyright © 2022 Mielke et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Vaccines and Antiviral Agents
Mielke, Dieter
Stanfield-Oakley, Sherry
Borate, Bhavesh
Fisher, Leigh H.
Faircloth, Katelyn
Tuyishime, Marina
Greene, Kelli
Gao, Hongmei
Williamson, Carolyn
Morris, Lynn
Ochsenbauer, Christina
Tomaras, Georgia
Haynes, Barton F.
Montefiori, David
Pollara, Justin
deCamp, Allan C.
Ferrari, Guido
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title_full Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title_fullStr Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title_full_unstemmed Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title_short Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies
title_sort selection of hiv envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity-mediating antibodies
topic Vaccines and Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791251/
https://www.ncbi.nlm.nih.gov/pubmed/34730393
http://dx.doi.org/10.1128/JVI.01643-21
work_keys_str_mv AT mielkedieter selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT stanfieldoakleysherry selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT boratebhavesh selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT fisherleighh selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT fairclothkatelyn selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT tuyishimemarina selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT greenekelli selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT gaohongmei selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT williamsoncarolyn selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT morrislynn selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT ochsenbauerchristina selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT tomarasgeorgia selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT haynesbartonf selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT montefioridavid selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT pollarajustin selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT decampallanc selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies
AT ferrariguido selectionofhivenvelopestrainsforstandardizedassessmentsofvaccineelicitedantibodydependentcellularcytotoxicitymediatingantibodies